Finanical Reports

Explore the landscape of Finanical Reports in China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data and insights on Finanical Reports to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Pfizer's Oral Ritlecitinib Meets Primary Endpoints in Phase III Nonsegmental Vitiligo Trials – Largest‑Ever Oral Systemic Program Clears Path for Global Filings
CompanyDrug

Pfizer’s Oral Ritlecitinib Meets Primary Endpoints in Phase III Nonsegmental Vitiligo Trials – Largest‑Ever Oral Systemic Program Clears Path for Global Filings

Pfizer Inc. (NYSE: PFE) announced that ritlecitinib (brand name Litfulo), an oral kinase inhibitor, met the primary endpoints in two Phase III trials in nonsegmental vitiligo, with data presented at…

Qyuns Therapeutics' Oturkibart Delivers Late‑Breaking Phase III Data in Prurigo Nodularis at EADV 2026 – IL‑4Rα Antibody Beats Placebo on Itch and Lesion Clearance

Qyuns Therapeutics’ Oturkibart Delivers Late‑Breaking Phase III Data in Prurigo Nodularis at EADV 2026 – IL‑4Rα Antibody Beats Placebo on Itch and Lesion Clearance

Abogen Biosciences Strikes Licensing and Option Deal with Novartis for ABO2203 – Up to $7.2 Billion to Advance the First mRNA‑Encoded T‑Cell Engager in Autoimmune Disease

Abogen Biosciences Strikes Licensing and Option Deal with Novartis for ABO2203 – Up to $7.2 Billion to Advance the First mRNA‑Encoded T‑Cell Engager in Autoimmune Disease

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Biogen Reports 8% YOY Sales Growth in Q1 2025, Driven by Rare Disease Therapies
Company

Biogen Reports 8% YOY Sales Growth in Q1 2025, Driven by Rare Disease Therapies

Fresenius Medical Care Reports 1% Revenue Growth in Q1 2025
Company

Fresenius Medical Care Reports 1% Revenue Growth in Q1 2025

Eli Lilly Reports 45% YOY Sales Growth in Q1 2025, Driven by Mounjaro and Zepbound
Company

Eli Lilly Reports 45% YOY Sales Growth in Q1 2025, Driven by Mounjaro and Zepbound

Dizal Pharmaceutical Reports Strong Revenue Growth in 2024 and Q1 2025
Company

Dizal Pharmaceutical Reports Strong Revenue Growth in 2024 and Q1 2025

Novartis Q1 2025 Results: Net Sales Up 15% YOY, Strong Growth in Key Brands
Company

Novartis Q1 2025 Results: Net Sales Up 15% YOY, Strong Growth in Key Brands

Fosun Pharma Reports Q1 2025 Revenues of RMB 9.42 Billion, Net Profits of RMB 765 Million
Company

Fosun Pharma Reports Q1 2025 Revenues of RMB 9.42 Billion, Net Profits of RMB 765 Million

AstraZeneca's Q1 2025 Results: 10% Revenue Growth, Oncology Segment Shines
Company

AstraZeneca’s Q1 2025 Results: 10% Revenue Growth, Oncology Segment Shines

Pfizer's Q1 2025 Results: Revenues Down 6% YOY Amid Paxlovid, IRA Impact
Company

Pfizer’s Q1 2025 Results: Revenues Down 6% YOY Amid Paxlovid, IRA Impact

Show More